1-(3,5-Dichloropyridin-2-yl)piperazine → [4-(3,5-Dichloropyridin-2-yl)piperazin-1-yl][4-(1,1-dioxo-1lambda6-isothiazolidin-2-yl)phenyl]methanone
반응식
[O:1]=[S:2]1(=[O:16])[CH2:6][CH2:5][CH2:4][N:3]1[C:7]1[CH:15]=[CH:14][C:10]([C:11]([OH:13])=O)=[CH:9][CH:8]=1.[Cl:17][C:18]1[C:19]([N:25]2[CH2:30][CH2:29][NH:28][CH2:27][CH2:26]2)=[N:20][CH:21]=[C:22]([Cl:24])[CH:23]=1>>[Cl:17][C:18]1[C:19]([N:25]2[CH2:30][CH2:29][N:28]([C:11]([C:10]3[CH:9]=[CH:8][C:7]([N:3]4[CH2:4][CH2:5][CH2:6][S:2]4(=[O:1])=[O:16])=[CH:15][CH:14]=3)=[O:13])[CH2:27][CH2:26]2)=[N:20][CH:21]=[C:22]([Cl:24])[CH:23]=1참가 물질
3
실험 절차
Using 4-(1,1-dioxo-1λ6-isothiazolidin-2-yl)benzoic acid (253 mg) described in Preparation Example 16 and 1-(3,5-dichloropyridin-2-yl)piperazine (229 mg) and by the reaction and treatment in the same manner as in Preparation Example 111, the title compound (340 mg) was obtained.
출처 및 근거
- ORD 기록
- ord-ef788dae34644f7f8bde575d944abad7
- 출처 데이터셋
- uspto-grants-2014_08